Q-omics provides the consensus-scored CCDC182 profile across patient tissues and cancer cell-line models. CCDC182 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CCDC182 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, CCDC182 RNA expression shows 6,816 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRP, and STAD as cancer lineages where CCDC182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC182 survival associations across molecular data types. CCDC182 RNA expression shows survival associations in the most cancer types (15), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC182 RNA expression–survival associations across cancer types. High CCDC182 expression shows unfavorable associations in LGG, THYM and DLBC, but favorable associations in LUAD, KIRP and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify LUAD as the clearest survival context for CCDC182 RNA expression.
This table summarizes CCDC182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC182 shows higher tumor expression in KIRP, KIRC and THCA. The KIRP box plot shows higher CCDC182 RNA expression in tumor versus normal tissue (log2 FC = +0.083, t-test p = .002).
This table shows molecular features associated with CCDC182 in patient tissues and cancer cell lines. In patient samples, CCDC182 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC182 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
